Contributions
Abstract: EP1673
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Objective and background: Alemtuzumab (ALZ) is a monoclonal antibody approved for the treatment of Multiple Sclerosis (MS). Severe Immune Thrombocytopenia (ITP) has been reported as a side effect up to 1% within 14-36 months after the first dose of ALZ. It has also been reported a decrease in the platelet count during the infusion, but always within normal limits. The objective of this paper is to report a case of severe acute non-immune thrombocytopenia during the first cycle of treatment with ALZ.
Methods: We present a case of severe acute non-immune thrombocytopenia, reversible and self-limiting, after the first dose on the first cycle of treatment with ALZ.
Results: 54-year-old woman with Relapsing-Remitting MS and 15 years evolution that despite receiving different treatments, has continued to present outbreaks; finally opting for ALZ treatment. After the first infusion, platelets 48000 UL were observed (201000 UL levels prior to treatment), no bruising and no evidence of bleeding. Treatment was suspended and platelets normalized, 155000 UL 72 hours later; so ALZ treatment was completed with good tolerance.
Conclusions: In the light of the approval of new MS treatments, it is important to pay attention to the potential onset of new side effects in our patients, as is our case, a severe non-immune thrombocytopenia during ALZ infusion.
Disclosure: Authors: Nothing to disclose
Abstract: EP1673
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Objective and background: Alemtuzumab (ALZ) is a monoclonal antibody approved for the treatment of Multiple Sclerosis (MS). Severe Immune Thrombocytopenia (ITP) has been reported as a side effect up to 1% within 14-36 months after the first dose of ALZ. It has also been reported a decrease in the platelet count during the infusion, but always within normal limits. The objective of this paper is to report a case of severe acute non-immune thrombocytopenia during the first cycle of treatment with ALZ.
Methods: We present a case of severe acute non-immune thrombocytopenia, reversible and self-limiting, after the first dose on the first cycle of treatment with ALZ.
Results: 54-year-old woman with Relapsing-Remitting MS and 15 years evolution that despite receiving different treatments, has continued to present outbreaks; finally opting for ALZ treatment. After the first infusion, platelets 48000 UL were observed (201000 UL levels prior to treatment), no bruising and no evidence of bleeding. Treatment was suspended and platelets normalized, 155000 UL 72 hours later; so ALZ treatment was completed with good tolerance.
Conclusions: In the light of the approval of new MS treatments, it is important to pay attention to the potential onset of new side effects in our patients, as is our case, a severe non-immune thrombocytopenia during ALZ infusion.
Disclosure: Authors: Nothing to disclose